Continued access to HIV treatment for children and teens
Treatments studied
Part of Infections clinical trials.
This trial provides continued access to Biktarvy (B/F/TAF) for children and adolescents who completed a previous Gilead HIV study. It ensures they can keep taking the medication without interruption.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished a qualifying Gilead HIV study (GS-US-292-0106, GS-US-380-1474, GS-US-311-1269, or GS-US-216-0128).
- You must agree to be in this study and sign a consent form.
- If you plan to switch to Biktarvy on day 1, your HIV viral load must be under 50 copies/mL at your last study visit.
- If you plan to switch to Biktarvy after day 1, your viral load must be under 50 copies/mL (or undetectable) before the switch.
- You cannot have any severe drug-related side effects or lab problems linked to Biktarvy components.
- You cannot have had to stop any part of Biktarvy before due to a bad reaction or intolerance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
This study looks at how well women with HIV stay in care while taking the medication Biktarvy (a combination of three drugs in one pill). It aims to understand their health outcomes and support better care.
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
This trial tests a new injectable HIV treatment (GS-3242 plus lenacapavir) compared to the daily pill Biktarvy for people just starting HIV therapy. If you qualify, you would receive shots every few weeks instead of taking a daily pill.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.